Kala Pharmaceuticals (KALA) Tops Q1 EPS by 19c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Wall St rises as oil slide offers respite after Fed rate hike
- Oil falls 2% to one-week low as Middle East supply disruption fears ease
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
- GlobalFoundries and Marvell expand SiGe capacity for optical networking
Kala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021 7:01 AM EDT-- Achieved $3.3 Million in Net Revenue in First Quarter --
-- Launched EYSUVIS® and Expanded Commercial Coverage to More than 69 Million Commercial Lives --
-- New Credit Facility Provides up to $125M --
-- Cash Runway Projected for at Least Two Years --
-- Conference Call and Webcast at 8:00 a.m. ET --
WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ: KALA), a biopharmaceutical company focused on the discovery, development... More
